last
decad
chikungunya
viru
chikv
evolv
geograph
isol
pathogen
viru
widespread
mani
part
africa
asia
recent
also
centraland
southamerica
although
chikv
infect
rare
fatal
diseas
evolv
chronic
stage
character
persist
polyarthralgia
joint
stiff
chronic
chikv
infect
sever
incapacit
patient
week
sever
year
initi
infect
despit
burden
chikv
infect
vaccin
antivir
avail
yet
current
therapi
therefor
symptomat
consist
administr
analges
antipyret
antiinfl
ammatori
agent
recent
sever
molecul
variou
viral
host
target
identifi
ed
chikv
inhibitor
chapter
summar
current
statu
develop
antivir
strategi
chikv
infect
chikungunya
viru
chikv
belong
alphaviru
genu
togavirida
famili
arthropodborn
viru
transmit
femal
mosquito
aed
speci
chikv
infect
caus
chikungunya
fever
character
abrupt
fever
rash
bilater
symmetr
arthralgia
chikvinfect
patient
acut
phase
follow
persist
disabl
polyarthr
sever
incapacit
patient
week
sever
month
despit
widespread
emerg
chikv
high
morbid
rate
associ
approv
vaccin
antivir
treatment
avail
moment
current
therapi
therefor
pure
base
relief
patient
symptom
consist
administr
analges
antipyret
antiinfl
ammatori
agent
paracetamol
nonsteroid
antiinfl
ammatori
drug
bed
rest
fl
uid
intak
use
aspirin
chikv
infect
avoid
risk
bleed
potenti
risk
develop
rey
syndrom
addit
use
system
corticosteroid
recommend
due
strong
rebound
effect
cessat
treatment
sever
case
patient
limit
respons
nonsteroid
antiinfl
ammatori
drug
diseasemodifi
antirheumat
drug
dmard
methotrex
hydroxychloroquin
sulphasalazin
administ
reliev
symptom
develop
novel
potent
antivir
drug
chikv
thu
urgent
need
antivir
agent
target
entri
envelop
virus
major
interest
sinc
inhibit
earli
step
viral
life
cycl
minim
cell
damag
caus
intracellular
viral
replic
addit
viral
entri
inhibitor
may
target
extracellular
compon
access
therefor
could
effect
lower
dosag
limit
toxic
chloroquin
antimalari
drug
also
shown
inhibit
vitro
replic
sever
virus
includ
hiv
sever
acut
respiratori
syndrom
sar
coronaviru
alphavirus
chloroquin
report
inhibit
chikv
entri
cell
possibl
rais
endosom
ph
thu
prevent
fusion
chikv
protein
endosom
membran
potenti
effect
chloroquin
treatment
assess
two
clinic
trial
fi
rst
clinic
trial
improv
symptom
chronic
phase
chikv
infect
report
follow
chloroquin
treatment
wherea
anoth
studi
fail
prove
effi
caci
chloroquin
treatment
acut
phase
chikv
infect
therefor
use
chloroquin
antichikv
antivir
requir
studi
prove
effect
determin
appropri
dosag
length
treatment
arbidol
broadspectrum
antivir
licens
russia
china
treatment
prophylaxi
infl
uenza
respiratori
infect
arbidol
also
report
inhibitor
chikv
infect
cell
mechan
antichikv
activ
total
elucid
arbidolresist
chikv
strain
could
select
shown
acquir
mutat
amino
acid
chikv
glycoprotein
may
involv
bind
host
receptor
recent
seri
arbidol
analogu
synthes
evalu
antichikv
activ
two
analogu
seri
iiie
iiif
inhibit
chikvinduc
cytopath
effect
cpe
select
indic
higher
parent
compound
arbidol
phenothiazin
clinic
approv
antipsychot
screen
assay
use
semliki
forest
viru
sfv
biosaf
surrog
chikv
six
compound
contain
core
includ
chlorpromazin
perphenazin
ethopropazin
thiethylperazin
thioridazin
methdilazin
identifi
ed
possibl
sfv
entri
inhibitor
antivir
activ
molecul
confi
rmed
use
recombin
chikv
strain
carri
luciferas
report
gene
chikvrluc
compar
sfvbase
screen
result
molecul
show
similar
potenc
chikvrluc
howev
ec
valu
determin
use
chikvrluc
higher
antivir
target
inhibitor
still
need
identifi
ed
epigallocatechin
gallat
egcg
major
constitu
green
tea
recent
egcg
report
modest
signifi
cant
antivir
activ
chikv
inhibit
chikv
entri
attach
target
cell
egcg
confi
rmed
use
pseudoparticl
carri
chikv
envelop
protein
rna
interfer
induc
small
interf
rna
sirna
homolog
sequenc
gene
need
silenc
small
interf
rna
nucleotid
long
dsrna
molecul
two
nucleotid
treatment
cell
exogen
sirna
result
assembl
rnainduc
silenc
complex
risc
degrad
specifi
c
complementari
mrna
molecul
consequ
protein
express
target
gene
markedli
reduc
small
interf
rna
sirna
sequenc
target
chikv
gene
report
signifi
cantli
reduc
chikv
titer
h
postinfect
transfect
vero
cell
howev
inhibitori
effect
sirna
transient
diminish
day
infect
sirna
could
thu
use
combin
antivir
effect
treatment
recent
studi
sirna
gener
potenti
activ
evalu
cell
cultur
anim
model
sirna
direct
well
combin
reduc
vitro
chikv
replic
vero
cell
interestingli
chikvinfect
mice
inject
day
postinfect
sirna
chikv
replic
complet
inhibit
highest
dose
sirna
test
mgkg
bodi
weight
plasmidbas
small
hairpin
rna
shrna
also
design
evalu
strategi
inhibit
chikv
replic
shrna
produc
shrnaplasmid
construct
result
intracellular
process
sirna
caus
specifi
c
knockdown
viral
rna
subsequ
inhibit
viral
protein
express
stabl
cell
clone
express
shrna
chikv
show
signifi
cant
sustain
inhibit
chikv
infect
addit
mice
pretreat
target
shrna
complet
protect
chikv
induc
diseas
surviv
observ
day
postinfect
untreat
anim
die
day
postinfect
harringtonin
cephalotaxin
alkaloid
deriv
cephalotaxu
harringtonia
report
asa
potent
inhibitor
chikv
minim
cytotox
addit
homoharringtonin
stabl
analogu
harringtonin
also
show
antichikv
activ
homoharringtonin
recent
approv
fda
treatment
chronic
myeloid
leukemia
harringtonin
homoharringtonin
found
suppress
product
viral
protein
like
inhibit
host
cell
protein
translat
machineri
addit
decreas
product
result
reduct
viral
replicas
complex
format
consequ
level
negativesens
rna
decreas
lead
reduc
synthesi
viral
positivesens
rna
genom
ribavirin
structur
analogu
guanosin
broadspectrum
antivir
drug
approv
fda
treatment
respiratori
syncyti
viru
infant
combin
pegyl
interferon
alpha
treatment
chronic
hepat
c
viru
infect
ribavirin
shown
inhibit
replic
chikv
vitro
addit
combin
ribavirin
report
result
asynergist
inhibitori
effect
chikv
replic
vero
cell
mechan
antivir
action
ribavirin
like
differ
differ
virus
metabolit
ribavirin
act
competit
inhibitor
inosin
monophosphatedehydrogenas
impdh
result
deplet
intracellular
gtp
dgtp
pool
predomin
mechan
ribavirin
inhibit
replic
rna
virus
fl
avivirus
paramyxovirus
shown
mediat
deplet
gtp
pool
suggest
mechan
ribavirin
inhibit
rna
viru
replic
includ
inhibit
viral
rna
cap
inhibit
viral
polymeras
lethal
mutagenesi
rna
genom
broadspectrum
antimetabolit
inhibit
replic
dna
rna
virus
uridin
analogu
competit
inhibit
orotidin
monophosph
decarboxylas
enzym
involv
de
novo
synthesi
pyrimidin
show
strong
inhibitori
effect
chikv
replic
vero
cell
ec
valu
mycophenol
acid
mpa
noncompetit
inhibitor
impdh
use
clinic
immunosuppress
prevent
reject
transplant
organ
mpa
inhibit
vitro
chikv
replic
inhibit
chikv
replic
appear
due
deplet
intracellular
gtp
pool
favipiravir
broadspectrum
antivir
agent
origin
discov
inhibitor
infl
uenza
viru
replic
cell
metabol
ribofuranosyl
form
shown
competit
inhibitor
incorpor
atp
gtp
viral
rnadepend
rna
polymeras
rdrp
howev
exact
mechan
action
total
clarifi
ed
yet
recent
report
defl
uorin
analogu
inhibit
vitro
replic
chikv
addit
oral
treatment
chikvinfect
mice
protect
mice
sever
neurolog
diseas
reduc
mortal
rate
lowlevel
chikv
variant
select
variant
carri
mutat
motif
rdrp
shown
respons
observ
resist
posit
highli
conserv
polymeras
ssrna
virus
chikv
protein
exhibit
rna
triphosphatasenucleosid
triphosphatas
activ
well
helicas
activ
within
ntermin
half
ctermin
half
encod
viral
cystein
proteas
requir
process
nonstructur
viral
polyprotein
addit
play
import
role
shut
host
cell
mrna
transcript
via
degrad
subunit
dnadirect
rna
polymeras
ii
also
inhibit
host
antivir
respons
suppress
transcript
type
ii
interferonstimul
jakstat
signal
highthroughput
screen
chikv
inhibitor
target
transcript
shut
natur
compound
deriv
shown
partial
block
activ
result
inhibit
chikv
replic
cell
cultur
anoth
studi
number
inhibitor
identifi
ed
use
computeraid
screen
procedur
one
lead
compound
compound
show
signifi
cant
antivir
activ
chikv
compound
predict
bind
central
portion
proteas
activ
site
recent
number
arylalkyliden
deriv
shown
inhibit
vitro
replic
chikv
inhibit
chikv
proteas
suggest
mechan
action
compound
cellular
furin
furinlik
proteas
involv
cleavag
viral
matur
protein
inhibit
cellular
furin
may
therefor
expect
inhibit
format
matur
viral
particl
decanoylrvkrchloromethyl
keton
decrvkrcmk
irrevers
furin
inhibitor
shown
inhibit
chikv
infect
vitro
via
inhibit
viral
glycoprotein
matur
combin
decrvkrcmk
chloroquin
result
addit
inhibitori
effect
chikv
replic
surprisingli
pretreat
cell
decrvkrcmk
reveal
signifi
cant
inhibit
viral
entri
indic
decrvkrcmk
treatment
could
alter
cleavag
protein
involv
chikv
endocytosi
earli
replic
step
molecul
could
even
inhibit
chikv
receptor
matur
prostratin
tetradecanoylphorbol
tpa
wellknown
tiglian
diterpenoid
basic
phorbol
carbon
skeleton
esterifi
ed
posit
due
chemic
structur
act
natur
analogu
diacylglycerol
induc
activ
protein
kinas
c
previous
prostratin
tpa
report
antivir
activ
hiv
prostratin
tpa
also
identifi
ed
potent
select
chikv
inhibitor
vitro
studi
requir
determin
mode
action
chikv
cellbas
screen
kinas
inhibitor
librari
six
kinas
inhibitor
found
inhibit
chikvassoci
cell
death
dosedepend
manner
molecul
four
compound
benzofuran
core
scaffold
one
pyrrolopyridin
one
thiazolcarboxamid
scaffold
use
imag
analysi
shown
chikvinfect
cell
treat
molecul
less
promin
apoptot
bleb
typic
chikv
cytopath
effect
moreov
compound
reduc
viral
titer
suggest
inhibit
virusinduc
cpe
compound
result
inhibit
kinas
involv
apoptosi
famili
highli
conserv
molecular
chaperon
includ
two
cytoplasm
isoform
stressinduc
constitut
express
gener
involv
matur
local
turnov
client
protein
cell
report
play
import
role
replic
mani
dna
rna
virus
hepat
b
viru
hepat
c
viru
human
cytomegaloviru
infl
uenza
viru
consequ
inhibitor
may
role
broad
er
spectrum
antivir
agent
two
inhibitor
report
chikv
replic
inhibitor
treatment
chikvinfect
mice
signifi
cantli
reduc
serum
viral
load
protein
kinas
c
pkc
activ
h
postinfect
protect
chikvinduc
infl
ammat
limb
infect
mice
coimmunoprecipit
studi
chikv
shown
interact
interestingli
knockdown
subunit
result
pronounc
inhibit
viral
replic
target
subunit
thought
involv
stabil
chikv
format
chikv
replic
complex
mechanist
studi
requir
unravel
role
replic
cycl
chikv
innat
immun
system
play
import
role
acut
phase
chikv
infect
detect
chikv
rna
tolllik
receptor
tlr
well
rigi
like
receptor
acut
phase
infect
believ
trigger
product
type
ifn
consequ
type
ifn
activ
transcript
interferonstimul
gene
isg
encod
protein
involv
host
antivir
defens
lead
clearanc
infect
therefor
activ
innat
immun
respons
could
interest
treatment
chikv
infect
treatment
inhibit
chikv
replic
vero
cell
dosedepend
manner
combin
ribavirin
result
synergist
antivir
effect
vitro
chikv
replic
chikv
strain
carri
mutat
report
sensit
antivir
activ
recombin
wildtyp
viru
role
innat
immun
toward
chikv
investig
use
stabl
hela
cell
line
express
express
cell
line
effi
cientli
inhibit
chikv
infect
block
earli
stage
viru
replic
chikv
variant
glutaminetolysin
mutat
posit
envelop
glycoprotein
prove
resist
antivir
activ
rigi
retino
acidinduc
gene
member
rigi
like
receptor
famili
recogn
viral
dsrna
lead
activ
multipl
antivir
factor
block
viral
infect
differ
stage
interestingli
chemic
enzymat
synthes
dsrna
molecul
expos
end
ppp
polyinosin
acidpolycytidyl
acid
rigi
agonist
report
induc
rigi
recent
shown
pretreat
cell
optim
triphosphoryl
rna
molecul
trigger
rigi
stimul
result
protect
chikv
infect
moreov
protect
respons
chikv
induc
ppp
rna
larg
independ
type
ifn
respons
result
suggest
potenti
effi
caci
rigi
agonist
antivir
treatment
chikv
infect
trigocherrierin
new
daphnan
diterpenoid
orthoest
isol
leav
trigonostemon
cherrieri
trigocherrierin
inhibit
chikv
cell
cultur
mechan
action
remain
elus
debromoaplysiatoxin
marin
toxin
isol
marin
cyanobacterium
trichodesmium
erythraeum
compound
signifi
cant
antivir
activ
chikv
nontox
concentr
compound
report
block
postentri
step
chikv
lifecycl
number
avon
apigenin
chrysin
naringenin
silybin
identifi
ed
inhibitor
chikv
subgenom
replicon
molecular
target
compound
still
unknown
global
reemerg
chikv
high
morbid
rate
associ
infect
emphas
need
develop
potent
antivir
agent
chikv
far
number
class
compound
inhibit
viral
replic
target
either
viral
host
factor
report
compound
rel
modest
activ
activ
infect
model
mice
assess
class
may
serv
start
point
design
specifi
c
select
inhibitor
chikv
replic
also
best
knowledg
inform
avail
yet
effect
antivir
chronic
stage
chikv
infect
recent
mous
model
chikvinduc
arthriti
chronic
joint
diseas
develop
help
evalu
chikv
antivir
agent
differ
stage
chikv
infect
sever
virus
belong
alphaviru
genu
particular
equin
enceph
virus
consid
potenti
bioterrorist
threat
designingdevelop
antivir
chikungunya
viru
may
import
develop
class
compound
panalphaviru
activ
could
thu
also
use
treatment
alphavirus
chikv
among
report
chikv
inhibitor
favipravir
ribavirin
arbidol
approv
previous
treatment
viral
infect
could
markedli
facilit
evalu
clinic
use
chikvinfect
patient
favipravir
drug
broadspectrum
antivir
activ
approv
japan
treatment
infl
uenza
viru
infect
current
also
evalu
western
africa
treatment
ebola
viru
infect
activ
demonstr
infect
compound
may
consid
treatment
infect
caus
chikv
howev
given
grow
number
patient
suffer
chikv
infect
may
justifi
ed
develop
specifi
c
chikvalphaviru
drug
highli
potent
drug
today
avail
treatment
infect
herp
virus
hiv
hepat
b
c
viru
without
doubt
also
possibl
invest
suffi
cient
effort
develop
highli
effect
safe
drug
treatment
perhap
even
prophylaxi
infect
alphavirus
